ArticleMedical devices (Auckland, N.Z.)2019
Technology update: dissolvable microneedle patches for vaccine delivery.
Article in Medical devices (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Dissolving microneedles for inflammatory diseases: Advances in formulation strategies and therapeutic applications.International journal of pharmaceutics: X · 2026Review
- Advances in veterinary drug and vaccine delivery: from conventional delivery methods to innovative transdermal approaches.Drug delivery and translational research · 2026Review
- Precision dosing of recombinant vaccinia vaccine via pillar-guided microneedle patch confers SARS-CoV-2 immunity.Scientific reports · 2025Article
- Booster Immunisation with Skin-Patch-Delivered Unadjuvanted SARS-CoV-2 Spike Protein Vaccine Is Safe and Immunogenic in Healthy Adults.Vaccines · 2025Article
- Recent progress of NIR light-controlled microneedles and therapeutic applications: A review study.Journal of materials science. Materials in medicine · 2025Review
- Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.Human vaccines & immunotherapeutics · 2025Article
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Review
- Microneedles: An Efficient Technique to Increase Transdermal Drug Delivery System.Current drug delivery · 2025Review
- Microneedles as a potential platform for improving antibiotic delivery to bacterial infections.Heliyon · 2024Review
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
- A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines.Nature biotechnology · 2024Article
- Fabrication Technology of Self-Dissolving Sodium Hyaluronate Gels Ultrafine Microneedles for Medical Applications with UV-Curing Gas-Permeable Mold.Gels (Basel, Switzerland) · 2024Article
- Detachable-dissolvable-microneedle as a potent subunit vaccine delivery device that requires no cold-chain.Vaccine: X · 2023Article
- Co-delivery of dendritic cell vaccine and anti-PD-1 antibody with cryomicroneedles for combinational immunotherapy.Bioengineering & translational medicine · 2023Article
- Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal Challenge.Journal of functional biomaterials · 2022Article
- A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity.iScience · 2022Article
- The Rise of Polymeric Microneedles: Recent Developments, Advances, Challenges, and Applications with Regard to Transdermal Drug Delivery.Journal of functional biomaterials · 2022Review
- Updates on Measles Incidence and Eradication: Emphasis on the Immunological Aspects of Measles Infection.Medicina (Kaunas, Lithuania) · 2022Review
- Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite vaccination representing one of the greatest advances of modern preventative medicine, there remain significant challenges in vaccine distribution, delivery and compliance. Dissolvable microarray patches or dissolving microneedles (DMN) have been proposed as an innovative vaccine delivery platform that could potentially revolutionize vaccine delivery and circumvent many of the challenges faced with current vaccine strategies. DMN, due to their ease of use, lack of elicitation of pain response, self-disabling nature and ease of transport and distribution, offer an attractive delivery option for vaccines. Additionally, as DMN inherently targets the uppermost skin layers, they facilitate improved vaccine efficacy, due to direct targeting of skin antigen-presenting cells. A plethora of publications have demonstrated the efficacy of DMN vaccination for a range of vaccines, with influenza receiving particular attention. However, before the viable adoption of DMN for vaccination purposes in a clinical setting, a number of fundamental questions must be addressed. Accordingly, this review begins by introducing some of the key barriers faced by current vaccination approaches and how DMN can overcome these challenges. We introduce some of the recent advances in the field of DMN technology, highlighting the potential impact DMN could have, particularly in countries of the developing world. We conclude by reflecting on some of the key questions that remain unanswered and which warrant further investigation before DMNs can be utilized in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.